Accurately reaching patients with rare hematologic disease
An unnamed client sought to improve targeting for a rare blood disorder patient population by shifting from modeled assumptions to observed clinical signals. The page states HealthVerity's Audiences solution can identify highly specific patient populations even at limited scale. The visible page content contains no specific outcome numbers or detailed results -- it primarily functions as a promotional gateway urging readers to "Download the full use case" for methodology and results.
The customer is anonymised in HealthVerity’s own case study — not withheld by us.
HealthVerity is a real-world-data marketplace aggregating claims, EHR and lab data from 75+ sources via a proprietary patient-matching layer.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by HealthVerity on its own site — read the original case study on info.healthverity.com ↗
Related use cases
- 01Symphony Health and dentsu health partner to efficiently reach rare disease patients
- 02Differentiating TYK2 inhibitors with real-world evidence in psoriasis
- 03How HealthVerity Audiences delivered 26.9x targeting precision for a rare kidney disease campaign
- 04Reducing targeting noise by supplementing claims with oncology labs: Metastatic breast cancer case study
- 05Accurately targeting chronic liver disease patients for specialty therapy
- 06Accelerating early RWE exploration without increasing analytic burden